The Tort Read
We read the tort before you spend a dollar: what stage it is in, what the lead economics look like, and which channels its buyers already crowd. You enter with a map, not a hunch.
Mass Tort Marketing
Mass tort marketing built on the tort read, not the settlement headline.
A mass tort is a market. Most firms bid on it blind, off a headline and a lead vendor's pitch. We read each tort first: its litigation stage, its lead economics, and where its claimants already watch and search. Then we build the advertising and intake, and measure every claimant to the signed retainer.
Free. One business day.
The model
Read the tort before you bid on it.
Mass tort advertising gets sold on the size of the settlement. That number tells you nothing about what a signed claimant costs to reach today. We start where the money actually moves: which torts are crowded, which are opening, and what the lead economics look like right now.
We publish that intelligence openly, tort by tort. It's the same read we run before we build a single campaign, so you enter a tort with a map instead of a hunch.
The tort read
Lifecycle stage, lead economics, and channel spend for every active mass tort, so you enter where the economics fit your firm.
The trace
Every claimant tracked from first touch through qualification to the signed retainer. No channel guesses, no gaps.
The market read
$141.6M a month in legal advertising analyzed across 35 US markets. We know which channels a tort's buyers already crowd.
Taqtics analysis of AdImpact data, Sep to Dec 2025
The intelligence
We publish the read on every active mass tort.
These are our own reports on the torts firms are advertising in now: the lifecycle stage, the lead economics, and the channel spend behind each one. Open the tort you're weighing. It's the read we run before we build.
NEC (Necrotizing Enterocolitis) Growth Rideshare Assault Growth PFAS / Forever Chemicals Emerging Talcum Powder Peak litigation Depo-Provera Growth Paraquat Peak litigation Hair Relaxer Growth Mesothelioma Peak litigation Camp Lejeune Declining Roundup / Glyphosate Declining Ozempic / GLP-1 Growth Social Media Addiction Peak litigation
What we build
Four pieces. Every claimant accounted for.
Concrete deliverables beat a vague "mass tort lead generation" promise. You get the read, the campaign, the qualified intake, and the trace to a signed retainer.
The Campaign Build
Streaming TV, social, and search, produced and bought in-house for the tort you pick. One message across every screen, sized to your market, not a rate card.
The Intake and Qualification Layer
A mass tort lead is only worth the criteria it clears. We build the intake and qualification flow so a claimant is screened against the tort criteria before it reaches your desk, and every one traces to its source.
The Signed-Retainer Report
A monthly read of every channel against retainers signed, not raw leads counted. You see the number that decides whether the campaign earned its cost.
Timing
Mass tort advertising is a timing decision first.
The same tort costs a fortune at peak and a fraction while it's emerging. Where a tort sits in its lifecycle drives what a claimant costs to reach and how long the wait to a payout runs. We map that stage before we recommend a dollar of spend.
Emerging and growth
Leads are cheaper and competition is thinner, but the litigation runs long. This is where a firm with patience builds a claimant base before the crowd arrives. We flag the torts that are opening and read whether the economics hold.
Peak and declining
The tort is crowded, leads are expensive, and settlement timelines can be shorter. Some torts are closing to new claimants entirely. We read where a tort actually sits so you don't buy into one on its way out.
Every one of our mass tort reports names the lifecycle stage up front, so the timing call is made on the read, not the headline.
Buy or build
Buying claimant leads or building your own flow: what each one costs.
A lead aggregator gets paid the moment a name lands, not when a claimant qualifies or signs. So it has no reason to screen the lead against the tort criteria. That's the wedge, and it's structural. Here's the difference in plain terms.
The bought claimant lead
- You buy claimant leads from an aggregator, priced per lead on delivery.
- The same lead is often sold to several firms chasing the same tort at once.
- Qualification stops at the sale. Nobody screens against the tort criteria for you.
- A lead that never qualifies still cost you full price.
The owned claimant flow
- Your own campaign brings the claimant: streaming, social, search, your site.
- You own the channel once you build it. It keeps producing after the spend.
- Every claimant is screened against the tort criteria before it reaches you.
- Each lead traces from first touch to signed retainer, channel by channel.
We build the owned side: streaming TV, paid search, and social, all screened to the tort criteria and measured to the signed retainer. When a bought list fills a gap, we score it against the same measure so you see its real cost.
What it costs
Priced on scope. Rolling monthly. No lock-in.
Cost follows the tort and the stage. An emerging tort and one at peak litigation need different builds, so we quote after the tort read, never from a rate card.
We quote after the free read, so the number matches the tort you're entering and where its claimants already are. No per-lead menu.
Get the read on my marketRolling 30-day terms
No lock-in. If the spend doesn't trace to signed cases, you leave.
Quoted after the read
We size the number to your market's real competitiveness, never a flat menu.
One firm per market
We work with one law firm per market. When you're in, a competitor in your city can't be.
Cost, timing, and leads
Mass tort marketing, answered.
What does mass tort marketing cost?
It follows the tort and the stage, and the sticker price on a lead is the wrong number to compare. A cheap lead looks cheap until you count the claimants who never qualify. The number that matters is cost per signed retainer, and that's the one the tort read is built to size before you commit a budget.
How much do mass tort leads cost per case?
It varies widely by tort, by litigation stage, and by how tightly the lead is qualified. A tort at peak litigation prices very differently than an emerging one. Our mass tort reports break down the lead economics tort by tort, each figure sourced.
Which mass tort should we advertise in?
Start with the stage, not the settlement headline. A tort at peak litigation is crowded and expensive, an emerging one is cheaper but slower to pay out. We read each active tort's lifecycle stage and channel spend so you enter where the economics fit your firm, not where the noise is loudest.
Should we buy mass tort leads or build our own claimant flow?
Buy for speed, build for cost that drops over time and leads you actually own. A bought claimant lead is priced on delivery and often sold to several firms at once. A claimant from your own campaign is screened against the tort criteria and traces to a signed retainer. Most firms with sustained volume build their own and buy only to fill gaps.
How does mass tort intake work?
Intake screens a claimant against the tort criteria before it becomes a case or a wasted call. Mass tort criteria are strict: diagnosis, exposure window, and documentation all have to line up. We build the qualification and routing layer so a lead that can't clear the criteria never buries one that can.
Does CTV advertising work for mass tort?
Yes, when it's measured to signed retainers and not just impressions. Connected TV reaches the households a tort's claimants sit in, at a scale broadcast can't target. It earns its cost only when the intake layer ties a viewer to a qualified claimant. That's how we run it.
Go deeper
The method behind the service, no pitch attached.
Your market
A tort just got more expensive.The read is free.
We read the tort you're weighing, the channels its claimants already crowd, and where your intake would leak. The read is free and comes back in one business day.
Free. One business day.